Exscientia (EXAI) Revenue & Revenue Breakdown
Exscientia Revenue Highlights
Latest Revenue (Y)
$24.96M
Latest Revenue (Q)
$5.29M
Main Segment (Y)
Licensing Fees - Upfront Payments and Research Funding
Main Geography (Y)
UNITED STATES
Exscientia Revenue by Period
Exscientia Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $24.96M | -24.14% |
2022-12-31 | $32.90M | 20.01% |
2021-12-31 | $27.41M | 107.98% |
2020-12-31 | $13.18M | 10.39% |
2019-12-31 | $11.94M | - |
Exscientia Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $5.29M | 117.70% |
2023-12-31 | $2.43M | -72.64% |
2023-09-30 | $8.88M | 195.48% |
2023-06-30 | $3.01M | -47.82% |
2023-03-31 | $5.76M | -29.74% |
2022-12-31 | $8.20M | 16.59% |
2022-09-30 | $7.03M | -18.75% |
2022-06-30 | $8.66M | -5.52% |
2022-03-31 | $9.16M | 120.82% |
2021-12-31 | $4.15M | -82.49% |
2021-09-30 | $23.69M | 5762.11% |
2021-06-30 | $404.13K | -94.43% |
2021-03-31 | $7.26M | 24.73% |
2020-12-31 | $5.82M | 367.54% |
2020-09-30 | $1.25M | -48.50% |
2020-06-30 | $2.42M | - |
2020-03-31 | $2.42M | 6.20% |
2019-12-31 | $2.28M | - |
2019-09-30 | $2.28M | - |
2019-06-30 | $2.28M | - |
2019-03-31 | $2.28M | - |
Exscientia Revenue Breakdown
Exscientia Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Licensing Fees - Opt-in Payments and Milestones Achieved | - | - | $18.58M |
Service Fees | $104.00K | - | - |
Licensing Fees - Upfront Payments and Research Funding | $19.98M | $26.55M | $8.32M |
Service fees | - | $670.00K | $452.00K |
Latest
Quarterly Revenue by Product
Product/Service | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 |
---|---|---|---|---|---|
Licensing Fees - Upfront Payments and Research Funding | $16.97M | $3.01M | $6.81M | $5.96M | $6.80M |
Service Fees | - | - | - | - | - |
Service fees | - | - | - | $334.00K | $336.00K |
Licensing Fees - Opt-in Payments and Milestones Achieved | - | - | - | - | - |
Latest
Exscientia Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
UNITED STATES | $14.38M | $21.00M | $22.20M |
FRANCE | $5.08M | - | - |
Other Countries Not Individually Disclosed | - | - | $3.56M |
Rest of Europe | $619.00K | $6.22M | - |
Latest
Exscientia Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BPMC | Blueprint Medicines | $249.38M | $128.18M |
KYMR | Kymera Therapeutics | $78.59M | $3.74M |
ADAP | Adaptimmune Therapeutics | $60.28M | $128.23M |
RXRX | Recursion Pharmaceuticals | $44.58M | $14.42M |
PIRS | Pieris Pharmaceuticals | $42.81M | - |
VECT | VectivBio | $27.34M | $676.00K |
RLAY | Relay Therapeutics | $25.55M | - |
EXAI | Exscientia | $24.96M | $5.29M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
MREO | Mereo BioPharma Group | $10.00M | - |
IPSC | Century Therapeutics | $2.23M | $791.00K |
LIFE | aTyr Pharma | $353.00K | $235.00K |
PDSB | PDS Bio | - | - |
ZURA | Zura Bio | - | - |
LPTX | Leap Therapeutics | - | - |
ELEV | Elevation Oncology | - | - |
UBX | Unity Bio | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
AVIR | Atea Pharmaceuticals | - | - |